Online journals: paying or delaying? by Nawrot, Tim et al.
,4CI
ffi
t{-"L
Correspondence
four subunits, and are often difficultto
break accurately owing to tablet shape
(eg, manual splitting of cylindrical
tablets), tablet size (small tablets are
more difficult to break accurately),
the technical quality ofthe score lines
(ie, limited depth), and the position
of the score lines (ie, only on one
side of the tablet). We have shown
that manual breaking of the new
tablets into eight subunits is easy and
reproducible, with low interindividual
variability and little weight loss.'
We have also shown that bio-
availability of zidovudine and
lamivudine given via the novel tablets
to healthy adult volunteers was similar
to that seen after administration of
marketed tablets containing the same
drugs.'We have now studied steady-
state pharmacokinetics of this dose
form in children with HIV and with
quinine in children with uncomplicated
malaria (unpublished data).
In our view, these multiple scored
tablets could also be an interesting
strategy by which to vary antibiotic
regimens according to bodyweight in
adrrlt nationïs
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Online journals: payi ng
or delaying?
In your Editorial on the perils of
journal and supplement publishing
flan lo, p 347)' you warn of financial
interests leading to bias in the
publication of manuscripts. On the
basis of our experience, we would like
to add a new dimension to editor-
imposed biases by mentioning the
policy of some online journals to
unexpectedly confront authors with
publication fees at a very late stage or
threatening to delay publication to an
unreasonable extent.
ln our example, the academic Editor-
in-Chief of an online journal appointed
an (unpaid) academic Managing Editor
and gave him full mandate to invite
articles for a special issue on a specific
topic. In sodoing,the Managing Editor
disseminated the journal's statement
that any peer-reviewed and accepted
articles would be published rapidly and
publication would be fully subsidised
by the journal. After peer review, our
invited manuscript was accepted and
transferred to a Production Editor.
1 month later, without the knowledge
ofthe Managing Editor, an anonymous
Production Editor requested by email
a payment for early publication.
After we refused, the Production
Editor gave us three options: (1) free
publication butwith at least a 1-.!-year
wait; (2) payment of a U5$1!!! "early"
publication fee; or (3) submission of
our article to another journal. These
Department of Error
options weÍe not negotiable. The
academic Managing Editor was not
made aware of these policies and the
Editor-in-Chief was never available to
commenr.
Our feeling is that this PubMed-
indexed journal is run by a commercial
company luring unpaid academic
Managing Editors into inviting authors
to submit to journals. We encourage
the Committee on Publication Ethics
to take action against such journals
and initiate a system whereby authors
can file complaints about journal
policies.
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Astfup A, RossnerS Vo n Gool L, et ol. Effects oflioglutidein thetreatment of obesity: a rand'omised, double-
blind, placebo-controlled study. Lancet 2009; 374: 16oG76-ln Ihis Article (Nov 7), the pÍoportion oí
patients with metabolic syndrome in table 1 (p 1608) should have been: 51% íoÍ placebo, 42/oÍor
liraglutide 1.2 mg, 362" for Iiraglutide 1.8 mg, 347" íor liraglutide2'4 mg, 47oÁÍot litaglutide 3 0 mg,
and 38"2 for oíistat.The second and third sentences oíthe seventh paragraph inthe Results section
(p r611) should have read: "The proportion of Patients with metabolic syndrome at week 20 decreased
by 64-75"/" in those treated with liraglutide 2 4 mg and 3'o m9.ïhe reduction in the placebo group was
35% and in the orlistat group was 21%." Finally, Ígure 44 contained incorrect data The correct frgure is
presented below.The erroís do not chànge any oíthe reported results
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